|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C19orf52 |
Gene summary for C19ORF52 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C19orf52 | Gene ID | 90580 |
| Gene name | translocase of inner mitochondrial membrane 29 | |
| Gene Alias | C19orf52 | |
| Cytomap | 19p13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006605 | UniProtAcc | Q9BSF4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 90580 | C19orf52 | P30T-E | Human | Esophagus | ESCC | 1.01e-16 | 5.14e-01 | 0.137 |
| 90580 | C19orf52 | P31T-E | Human | Esophagus | ESCC | 5.46e-23 | 3.69e-01 | 0.1251 |
| 90580 | C19orf52 | P32T-E | Human | Esophagus | ESCC | 2.22e-20 | 3.95e-01 | 0.1666 |
| 90580 | C19orf52 | P36T-E | Human | Esophagus | ESCC | 1.32e-16 | 5.29e-01 | 0.1187 |
| 90580 | C19orf52 | P37T-E | Human | Esophagus | ESCC | 2.40e-08 | 1.64e-01 | 0.1371 |
| 90580 | C19orf52 | P39T-E | Human | Esophagus | ESCC | 5.38e-09 | 2.11e-01 | 0.0894 |
| 90580 | C19orf52 | P40T-E | Human | Esophagus | ESCC | 1.45e-03 | 2.07e-01 | 0.109 |
| 90580 | C19orf52 | P42T-E | Human | Esophagus | ESCC | 5.50e-12 | 3.13e-01 | 0.1175 |
| 90580 | C19orf52 | P44T-E | Human | Esophagus | ESCC | 6.64e-03 | 1.79e-01 | 0.1096 |
| 90580 | C19orf52 | P47T-E | Human | Esophagus | ESCC | 5.30e-12 | 2.07e-01 | 0.1067 |
| 90580 | C19orf52 | P48T-E | Human | Esophagus | ESCC | 3.02e-05 | 1.42e-01 | 0.0959 |
| 90580 | C19orf52 | P49T-E | Human | Esophagus | ESCC | 8.98e-08 | 6.29e-01 | 0.1768 |
| 90580 | C19orf52 | P52T-E | Human | Esophagus | ESCC | 1.22e-20 | 4.37e-01 | 0.1555 |
| 90580 | C19orf52 | P54T-E | Human | Esophagus | ESCC | 7.57e-09 | 2.91e-01 | 0.0975 |
| 90580 | C19orf52 | P57T-E | Human | Esophagus | ESCC | 7.74e-12 | 1.49e-01 | 0.0926 |
| 90580 | C19orf52 | P61T-E | Human | Esophagus | ESCC | 1.21e-07 | 2.31e-01 | 0.099 |
| 90580 | C19orf52 | P62T-E | Human | Esophagus | ESCC | 9.85e-25 | 4.09e-01 | 0.1302 |
| 90580 | C19orf52 | P65T-E | Human | Esophagus | ESCC | 8.00e-13 | 1.97e-01 | 0.0978 |
| 90580 | C19orf52 | P74T-E | Human | Esophagus | ESCC | 1.34e-13 | 3.48e-01 | 0.1479 |
| 90580 | C19orf52 | P75T-E | Human | Esophagus | ESCC | 1.28e-31 | 5.85e-01 | 0.1125 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |